318 related articles for article (PubMed ID: 26626320)
41. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
Lau YH; Leta V; Rukavina K; Parry M; Ann Natividad J; Metta V; Chung-Faye G; Chaudhuri KR
J Neural Transm (Vienna); 2022 Jul; 129(7):889-894. PubMed ID: 35503480
[TBL] [Abstract][Full Text] [Related]
42. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
[TBL] [Abstract][Full Text] [Related]
43. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
44. Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
Bauer A; Cassel W; Benes H; Kesper K; Rye D; Sica D; Winkelman JW; Bauer L; Grieger F; Joeres L; Moran K; Schollmayer E; Whitesides J; Carney HC; Walters AS; Oertel W; Trenkwalder C;
Neurology; 2016 May; 86(19):1785-93. PubMed ID: 27164714
[TBL] [Abstract][Full Text] [Related]
45. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
LeWitt PA; Lyons KE; Pahwa R;
Neurology; 2007 Apr; 68(16):1262-7. PubMed ID: 17438216
[TBL] [Abstract][Full Text] [Related]
46. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
[TBL] [Abstract][Full Text] [Related]
47. Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.
Ohta K; Osada T
Clin Neuropharmacol; 2015; 38(6):231-5. PubMed ID: 26536020
[TBL] [Abstract][Full Text] [Related]
48. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
[TBL] [Abstract][Full Text] [Related]
50. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
51. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Frampton JE
CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
[TBL] [Abstract][Full Text] [Related]
52. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
Baldwin CM; Keating GM
CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
[TBL] [Abstract][Full Text] [Related]
53. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
[TBL] [Abstract][Full Text] [Related]
54. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
LeWitt PA; Boroojerdi B; Surmann E; Poewe W; ;
J Neural Transm (Vienna); 2013 Jul; 120(7):1069-81. PubMed ID: 23208198
[TBL] [Abstract][Full Text] [Related]
55. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S
J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520
[TBL] [Abstract][Full Text] [Related]
56. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
[TBL] [Abstract][Full Text] [Related]
57. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
[TBL] [Abstract][Full Text] [Related]
58. Night-time use of rotigotine in advanced Parkinson's disease.
Canesi M; Mariani CB; Isaias IU; Pezzoli G
Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
[TBL] [Abstract][Full Text] [Related]
59. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
Schnitzler A; Leffers KW; Häck HJ
Parkinsonism Relat Disord; 2010 Sep; 16(8):513-6. PubMed ID: 20605106
[TBL] [Abstract][Full Text] [Related]
60. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Giladi N; Boroojerdi B; Surmann E
J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
